These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28671136)

  • 1. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.
    Banno H; Andrzejewski KL; McDermott MP; Murphy A; Majumder M; de Blieck EA; Auinger P; Cudkowicz ME; Atassi N
    J Huntingtons Dis; 2017; 6(2):149-156. PubMed ID: 28671136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
    Huntington Study Group
    Neurology; 2001 Aug; 57(3):397-404. PubMed ID: 11502903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.
    McGarry A; McDermott MP; Kieburtz K; Fung WLA; McCusker E; Peng J; de Blieck EA; Cudkowicz M;
    Neurology; 2019 Apr; 92(14):e1643-e1651. PubMed ID: 30850442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in Huntington's disease: a 2-year study on minocycline.
    Bonelli RM; Hödl AK; Hofmann P; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Nov; 19(6):337-42. PubMed ID: 15486519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
    McGarry A; McDermott M; Kieburtz K; de Blieck EA; Beal F; Marder K; Ross C; Shoulson I; Gilbert P; Mallonee WM; Guttman M; Wojcieszek J; Kumar R; LeDoux MS; Jenkins M; Rosas HD; Nance M; Biglan K; Como P; Dubinsky RM; Shannon KM; O'Suilleabhain P; Chou K; Walker F; Martin W; Wheelock VL; McCusker E; Jankovic J; Singer C; Sanchez-Ramos J; Scott B; Suchowersky O; Factor SA; Higgins DS; Molho E; Revilla F; Caviness JN; Friedman JH; Perlmutter JS; Feigin A; Anderson K; Rodriguez R; McFarland NR; Margolis RL; Farbman ES; Raymond LA; Suski V; Kostyk S; Colcher A; Seeberger L; Epping E; Esmail S; Diaz N; Fung WL; Diamond A; Frank S; Hanna P; Hermanowicz N; Dure LS; Cudkowicz M;
    Neurology; 2017 Jan; 88(2):152-159. PubMed ID: 27913695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
    Schilling G; Coonfield ML; Ross CA; Borchelt DR
    Neurosci Lett; 2001 Nov; 315(3):149-53. PubMed ID: 11716985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study.
    Aylward EH; Rosenblatt A; Field K; Yallapragada V; Kieburtz K; McDermott M; Raymond LA; Almqvist EW; Hayden M; Ross CA
    Brain Res Bull; 2003 Dec; 62(2):137-41. PubMed ID: 14638387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
    Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
    Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
    Sešok S; Bolle N; Kobal J; Bucik V; Vodušek DB
    Psychiatr Danub; 2014 Sep; 26(3):239-48. PubMed ID: 25191771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.
    Schobel SA; Palermo G; Auinger P; Long JD; Ma S; Khwaja OS; Trundell D; Cudkowicz M; Hersch S; Sampaio C; Dorsey ER; Leavitt BR; Kieburtz KD; Sevigny JJ; Langbehn DR; Tabrizi SJ;
    Neurology; 2017 Dec; 89(24):2495-2502. PubMed ID: 29142089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.
    Biglan KM; Dorsey ER; Evans RV; Ross CA; Hersch S; Shoulson I; Matson W; Kieburtz K;
    J Huntingtons Dis; 2012; 1(1):65-9. PubMed ID: 25063191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of coenzyme Q10 tolerability in Huntington's disease.
    Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I
    Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minocycline safety and tolerability in Huntington disease.
    Huntington Study Group
    Neurology; 2004 Aug; 63(3):547-9. PubMed ID: 15304592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease.
    Drew CJG; Quinn L; Hamana K; Williams-Thomas R; Marsh L; Dimitropoulou P; Playle R; Griffin BA; Kelson M; Schubert R; Muratori L; Reilmann R; Rosser A; Busse M
    Phys Ther; 2019 Sep; 99(9):1201-1210. PubMed ID: 31101920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole in Huntington's disease (HD): an open label study with one year follow up.
    Seppi K; Mueller J; Bodner T; Brandauer E; Benke T; Weirich-Schwaiger H; Poewe W; Wenning GK
    J Neurol; 2001 Oct; 248(10):866-9. PubMed ID: 11697523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of remacemide hydrochloride in Huntington's disease.
    Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I
    Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease.
    McGarry A; Auinger P; Kieburtz KD; Bredlau AL; Hersch SM; Rosas HD
    Neurol Clin Pract; 2022 Apr; 12(2):131-138. PubMed ID: 35747889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.